Abstract P252: IMM-1-104: a novel, oral, selective dual-MEK …
2021年12月1日 · IMM-1-104 is a novel dual-MEK inhibitor that is designed to disrupt phosphorylation of MEK and subsequently prevent activation of ERK1 and ERK2 (ERK). IMM …
Pipeline - Immuneering Corporation
Our lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as …
胰腺导管腺癌明显缩小！IMM-1-104联合化疗临床应答效果喜人
2025年1月21日 · imm-1-104是一种新型双重mek抑制剂，旨在破坏mek的磷酸化，进而阻止erk1和erk2(erk)的激活。 IMM-1-104的双MEK机制可抵制RAF对MEK的激活，而且它的药物半衰期 …
KRAS突变胰腺癌：又一靶向药，获FDA加速许可进入临床 - 知乎
美国专家建议的临床试验IMM-1-104是一种具有高选择性的第三代小分子MEK抑制剂，旨在实现泛RAS活性。 该药物通过驱动深度循环抑制来调节MAPK通路的信号传导动力学，能在剥夺肿瘤 …
FDA 授予 IMM-1-104 快速通道资格_患者_研究_治疗 - 搜狐
12 小时之前 · imm-1-104 针对对 pd-1-/pd-l1 抑制剂不耐受的 nras 突变黑色素瘤患者，获得 fda 快速通道认定。 FDA 授予 IMM-1-104（Immuneering Corp.）快速通道资格，用于治疗无法切 …
IMM-1-104 (IMM-1-104) - 药物靶点：MEK1 x MEK2_在研适应 …
The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors …
1524P Preliminary phase I safety and activity of IMM-1-104, an …
IMM-1-104, a novel MEK inhibitor, blocks both MEK and ERK phosphorylation preventing CRAF bypass and hyperactivation of MEK. A short half-life of 2 hours combined with once daily …
FDA 授予 IMM-1-104 快速通道资格 - 知乎 - 知乎专栏
2025年1月8日 · IMM-1-104 是一种新型口服双重 MEK1/2 抑制剂，旨在实现通用 RAS 活性，选择性地对癌细胞产生比健康细胞更大的影响。 它每天给药一次，可实现对 MAPK 通路的深度周 …
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 …
2023年6月5日 · IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway …
IMM-1-104, a novel MEK inhibitor, blocks both MEK and ERK phosphorylation preventing CRAF bypass and hyperactivation of MEK. A short half-life of 2 hours combined with once daily …